CY1111467T1 - Μορια ανθρωπινου αντισωματος για την il-13 - Google Patents

Μορια ανθρωπινου αντισωματος για την il-13

Info

Publication number
CY1111467T1
CY1111467T1 CY20111100456T CY111100456T CY1111467T1 CY 1111467 T1 CY1111467 T1 CY 1111467T1 CY 20111100456 T CY20111100456 T CY 20111100456T CY 111100456 T CY111100456 T CY 111100456T CY 1111467 T1 CY1111467 T1 CY 1111467T1
Authority
CY
Cyprus
Prior art keywords
motorcycle
ill
human response
antibody molecules
hodgkin
Prior art date
Application number
CY20111100456T
Other languages
Greek (el)
English (en)
Inventor
Phillip David Monk
Lutz Jermutus
Ralph Raymond Minter
Celia Patricia Shorrock
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0407315.1A external-priority patent/GB0407315D0/en
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of CY1111467T1 publication Critical patent/CY1111467T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY20111100456T 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13 CY1111467T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US48751203P 2003-07-15 2003-07-15
US55821604P 2004-03-31 2004-03-31
GBGB0407315.1A GB0407315D0 (en) 2003-07-15 2004-03-31 Human antibody molecules
US57379104P 2004-05-24 2004-05-24
EP04743400A EP1646656B1 (fr) 2003-07-15 2004-07-15 Molecules d'anticorps humains anti-il13

Publications (1)

Publication Number Publication Date
CY1111467T1 true CY1111467T1 (el) 2015-08-05

Family

ID=44535047

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100456T CY1111467T1 (el) 2003-07-15 2011-05-16 Μορια ανθρωπινου αντισωματος για την il-13

Country Status (8)

Country Link
JP (3) JP5519567B2 (fr)
KR (1) KR101073590B1 (fr)
AU (1) AU2011200308B2 (fr)
CY (1) CY1111467T1 (fr)
HK (3) HK1097853A1 (fr)
MX (1) MXPA06000258A (fr)
NO (2) NO338853B1 (fr)
RU (1) RU2009148270A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016015785A (es) * 2014-06-18 2017-04-25 Medimmune Llc Metodos y medios de cultivo celular que comprenden n-acetilcisteina.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5010793A (en) * 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
EP1578912A4 (fr) * 2001-10-26 2007-12-26 Centocor Inc Proteines muteines il-13, anticorps, compositions, procedes et utilisations
EP1461428B1 (fr) * 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Méthode de production d'anticorps hybrides
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AU2003260748A1 (en) * 2002-08-30 2004-03-19 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
KR20060054312A (ko) 2006-05-22
HK1155185A1 (zh) 2012-05-11
AU2011200308A1 (en) 2011-02-17
JP2016047843A (ja) 2016-04-07
JP5922686B2 (ja) 2016-05-24
NO342727B1 (no) 2018-07-30
JP2014101372A (ja) 2014-06-05
NO20160707A1 (no) 2016-04-27
NO20060730L (no) 2006-04-10
NO338853B1 (no) 2016-10-24
AU2011200308B2 (en) 2011-07-28
JP5519567B2 (ja) 2014-06-11
MXPA06000258A (es) 2006-07-03
HK1097853A1 (en) 2007-07-06
HK1216427A1 (zh) 2016-11-11
RU2009148270A (ru) 2011-06-27
KR101073590B1 (ko) 2011-10-14
JP2011147454A (ja) 2011-08-04

Similar Documents

Publication Publication Date Title
MY144906A (en) Human antibodies against il13 and therapeutic uses
WO2005007699A8 (fr) Molecules d'anticorps humains anti-il13
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
CY1120887T1 (el) Αντισωματα που προσδενουν il-4 και/ή il-13 και οι χρησεις τους
TNSN08333A1 (en) Thymic stromal lymphopoietin (tslp) antibodies and uses thereof
NO20054223L (no) Antistoffmolekyler som har spesifisitet for human IL-1beta
MX2009010765A (es) Anticuerpos anti-ige.
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
WO2005123126A3 (fr) Anticorps anti-interleukine-13 et leurs utilisations
DK1185294T3 (da) Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser
EP2347767A3 (fr) Régulation immunitaire basée sur le ciblage de molécules d'activation précoce
CY1111467T1 (el) Μορια ανθρωπινου αντισωματος για την il-13
DE602005026260D1 (de) Natürliche igm-antikörper und inhibitoren davon
TNSN08175A1 (en) Human antibodies against il-13 and therapeutic uses
Habibi et al. Effectiveness of dialectical behavior therapy in improving symptoms of patients with dysthymic disorder
TH101957A (th) แอนตี้บอดี้ต่อ il-13 ของมนุษย์และการใช้ทางอายุรเวช
Kang et al. A Study on Psychological Effect of Natural Element in Rest Space of Office
Phillips The efficacy of low back strengthening with and without Chiropractic adjustment in the treatment of chronic mechanical low back pain
TH98075B (th) แอนตี้-tslp แอนตี้บอดี้
Roelants Effect of vibration training on muscle strength, muscle performance and velocity-related mechanical muscle characteristics
Yong Effects of protein glutaminase treatments on structure and functional properties of cereal proteins
Kolt et al. Physical activity for health: a focus on the ageing population
IL186666A0 (en) Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
De Lepeleire Veranderende denkpatronen over ouderenzorg: van invalidatie naar revalidatie
TH98075A (th) แอนตี้-tslp แอนตี้บอดี้